Equity Overview
Price & Market Data
Price: $1.54
Daily Change: +$0.03 / 1.95%
Daily Range: $1.48 - $1.55
Market Cap: $75,685,220
Daily Volume: 65,257
Performance Metrics
1 Week: -1.28%
1 Month: -3.14%
3 Months: 19.38%
6 Months: 15.54%
1 Year: -29.03%
YTD: -26.67%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.